UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration‐sensitive prostate cancer: A multicenter retrospective study

International journal of urology, 2022-05, Vol.29 (5), p.478-479

Shiota, Masaki

2022

Volltextzugriff (PDF)

Editorial Comment from Dr Shiota to Stage and cancer‐specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population‐based study

International journal of urology, 2021-12, Vol.28 (12), p.1253-1253

Shiota, Masaki

2021

Volltextzugriff (PDF)

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer

International journal of urology, 2016-05, Vol.23 (5), p.360-369

2016

Volltextzugriff (PDF)

Unrecognized Pitfall When Doing Nerve-Sparing Surgery in Radical Prostatectomy

Annals of surgical oncology, 2021-09, Vol.28 (9), p.4775-4776

2021

Volltextzugriff (PDF)

Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer

Current cancer drug targets, 2023-01, Vol.23 (6), p.428-432

2023

Volltextzugriff (PDF)

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

Cancer science, 2022-05, Vol.113 (5), p.1731-1738

2022

Volltextzugriff (PDF)

Androgen receptor mutations for precision medicine in prostate cancer

Endocrine-related cancer, 2022-10, Vol.29 (10), p.R143-R155

2022

Volltextzugriff (PDF)

Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer

The pharmacogenomics journal, 2021-02, Vol.21 (1), p.102-105

2021

Volltextzugriff (PDF)

Novel mechanism of androgen receptor regulation through switching by long non‐coding RNA LINC01126

Clinical and translational discovery, 2024-02, Vol.4 (1), p.n/a

2024

Volltextzugriff (PDF)

Editorial Comment from Dr Shiota to Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy

International journal of urology, 2014-06, Vol.21 (6), p.583-584

Shiota, Masaki

2014

Volltextzugriff (PDF)

Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer

Cancer Immunology, Immunotherapy, 2022-03, Vol.71 (3), p.727-736

2022

Volltextzugriff (PDF)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old

Cancer science, 2021-08, Vol.112 (8), p.3074-3082

2021

Volltextzugriff (PDF)

Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer

Cancer research (Chicago, Ill.), 2013-05, Vol.73 (10), p.3109-3119

2013

Volltextzugriff (PDF)

Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients

Cancer science, 2022-09, Vol.113 (9), p.3120-3133

2022

Volltextzugriff (PDF)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants

Cancer science, 2018-10, Vol.109 (10), p.3224-3234

2018

Volltextzugriff (PDF)

Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target

Journal of molecular endocrinology, 2011-08, Vol.47 (1), p.R25-R41

2011

Volltextzugriff (PDF)

Continuing enzalutamide with docetaxel in castration-resistant prostate cancer

The lancet oncology, 2022-11, Vol.23 (11), p.1345-1347

Shiota, Masaki

2022

Volltextzugriff (PDF)

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data

Cancers, 2022-08, Vol.14 (17), p.4161

2022

Volltextzugriff (PDF)

Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer

Endocrine-related cancer, 2012-12, Vol.19 (6), p.R243-R253

2012

Volltextzugriff (PDF)

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Scientific reports, 2022-05, Vol.12 (1), p.8535-8535, Article 8535

2022

Volltextzugriff (PDF)

Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer

Urologia internationalis, 2019-01, Vol.103 (2), p.125-136

2019

Volltextzugriff (PDF)

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy

Cancers, 2022-05, Vol.14 (11), p.2696

2022

Volltextzugriff (PDF)

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer

British journal of cancer, 2022-11, Vol.127 (9), p.1680-1690

2022

Volltextzugriff (PDF)

Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

IJU case reports, 2021-07, Vol.4 (4), p.219-220

2021

Volltextzugriff (PDF)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer

International journal of molecular sciences, 2019-08, Vol.20 (16), p.3936

2019

Volltextzugriff (PDF)

1 – 25 von 595

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(509)
Mit Volltextzugriff
(496)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Urology
(43)
International Journal Of Urology
(34)
Cancer Science
(17)
Journal Of Clinical Oncology
(15)
Anticancer Research
(14)
The Prostate
(14)
Cancer Research
(12)
Urologic Oncology
(10)
Endocrine-Related Cancer
(9)
Anticancer Research/anticancer Research
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration‐sensitive prostate cancer: A multicenter retrospective study

Editorial Comment from Dr Shiota to Stage and cancer‐specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population‐based study

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer

Unrecognized Pitfall When Doing Nerve-Sparing Surgery in Radical Prostatectomy

Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

Androgen receptor mutations for precision medicine in prostate cancer

Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer

Novel mechanism of androgen receptor regulation through switching by long non‐coding RNA LINC01126

Editorial Comment from Dr Shiota to Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy

Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old

Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer

Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants

Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target

Continuing enzalutamide with docetaxel in castration-resistant prostate cancer

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data

Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer

Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer

Suchergebnisse filtern